From the Research
The most effective treatment for Meige syndrome is onabotulinum toxin type A (OBTA) injections, which have been shown to significantly reduce dystonia severity with minimal side effects. According to the most recent and highest quality study 1, OBTA injections resulted in a significant reduction in dystonia severity, with a mean Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) score decrease from 8.89 to 2.88 after 14 days. The clinical response was more pronounced in the treatment of blepharospasm than in oromandibular dystonia.
Some key points to consider when treating Meige syndrome with OBTA injections include:
- The mean age of patients in the study was 67.7 years, with a female-to-male ratio of 3.5:1
- The most reported side effect was ptosis, with a 7.3% incidence
- The effect of OBTA was more pronounced in the treatment of blepharospasm than in oromandibular dystonia
- The study included 41 participants, and the results support the use of OBTA as an effective and safe therapeutic option for treating Meige's syndrome
It's worth noting that while other studies, such as 2, 3, 4, and 5, also support the use of botulinum toxin injections for Meige syndrome, the most recent and highest quality study 1 provides the strongest evidence for the effectiveness and safety of OBTA injections.
In terms of treatment approach, OBTA injections should be considered as a first-line treatment for Meige syndrome, given their efficacy and safety profile. Other treatment options, such as oral medications and supportive therapies, may be considered in conjunction with OBTA injections or in cases where OBTA is not effective or tolerated. However, the primary treatment approach should prioritize OBTA injections, as supported by the most recent and highest quality evidence 1.